Derivative exercise or conversion — not an open-market buy.
Traded Jul 7, 2026 · Filed Jul 9, 2026
Corcept Therapeutics's Chief Development Officer sold $89K of Corcept Therapeutics shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$89,048
Shares × reported transaction price
68 days after results of Apr 30, 2026, 22 days before results of Jul 29, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −3.8% | −0.1% | −3.7% |
| 30 days | +22.5% | +2.8% | +19.7% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Officer sold ~$419K of Corcept Therapeutics
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.